Author

Ashley Dung

Ionis Pharmaceuticals (United States)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Genetic & Genomic Medicine· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Andrew T. Watt· 1 shared Christopher J. Torio· 1 shared Dan DominissiniiD· 1 shared Harikrishna Thulaseedharan· 1 shared Isaac TangiD· 1 shared Joseph G. GleesoniD· 1 shared Julie DouvilleiD· 1 shared Konstantina Skourti-StathakiiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperGenetic & Genomic Medicine

Andrew T. Watt

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

ASXL3 truncating patient variants mediate transcriptional gain-of-function and are antisense oligonucleotide-responsive

Yuji Nakamura, Toan Nguyen, Nofar Mor, Dan Dominissini, Isaac Tang, Christopher J. Torio, Harikrishna Thulaseedharan, Rachel Yibei Zhou, Wenshu Zhang, Konstantina Skourti-Stathaki, Julie Douville, Laurence Mignon, Ashley Dung, Susan M. Freier, Andrew T. Watt, , Joseph G. Gleeson

The paper shows ASXL3 truncating variants cause disease via gain-of-function, not loss-of-function, and demonstrates antisense oligonucleotides can reverse the transcriptional effects.

medRxiv · Jul 22, 2026 · PreprintGenetic & Genomic Medicine